EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sutro Biopharma's Enterprise Value is $-2.7 Mil.
Sutro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-115.9 Mil. Therefore, Sutro Biopharma's EV-to-FCF for today is 0.02.
The historical rank and industry rank for Sutro Biopharma's EV-to-FCF or its related term are showing as below:
STRO'
s EV-to-FCF Range Over the Past 10 Years
Min: -126.91 Med: -1.74 Max: 32.56
Current: 0.02
During the past 8 years, the highest EV-to-FCF of Sutro Biopharma was 32.56. The lowest was -126.91. And the median was -1.74.
STRO's EV-to-FCF is ranked better than 96.4% of 389
companies
in the Biotechnology industry
Industry Median: 6.49
vs STRO: 0.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Sutro Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sutro Biopharma's EV-to-FCF
For the Biotechnology subindustry, Sutro Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's EV-to-FCF falls into.
Sutro Biopharma's current Enterprise Value is $-2.7 Mil.
Sutro Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-115.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (NAS:STRO) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sutro Biopharma's PE Ratio for today is calculated as:
Sutro Biopharma's share price for today is $4.23.
Sutro Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sutro Biopharma EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Sutro Biopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sutro Biopharma (Sutro Biopharma) Business Description
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STRO has been successfully added to your 